Innovation, R&D and Commercialisation Division
Our innovation, product development and commercialisaton services are designed to support through during the entire product development journey to help you de-risk projects and maximimise the probability of success.
A summary of our most popular services is provided below. We also regularly conduct bespoke projects for out clients, so please do not hesitate to contact us to informally discuss how we might be able to help
Innovation Strategy, Portfolio and R&D planning
We can help you develop your innovation/ product development strategy and support you in understanding markets, how to identify opportunities and how to convert these into product development opportunities. This can be in the form of training, in house workshops or specific projects
Market/Competitor/ Technology analysis and reports
Market, competitor and Technology reports are frequently commissioned to understand the landscape and are designed and scoped to understand the specific needs of the client. Typically, they either have a market or technology emphasis (or a mixture of both) and provide information on competitor solutions (e.g., technology segmentation, product positioning and claims) (either in market, near to market or early stage), and can be scoped to include information on market size and segmentation, patient pathways and clinical guidelines and can include an overview of regulatory and reimbursement considerations.
Companies use market/ competitor and technology analysis to make Go/No decisions with regard to investment decisions, use such reports as a means to identify new technologies or companies to acquire via licensing or acquisition activities or commercial partnerships or simply use the analysis to improve product design and to ensure product differentiation.
One of the key reasons why medical products fail in the market place is that the value proposition has not been developed early enough to influence further development work and often results in non-optimal claims being defined and poor clinical trial design that does not gather the right evidence to improve the probability of adoption.
Medilink provides an early-stage value proposition service to align the product or service to quality indicators that govern flows of money and as such are highly useful in d developing evidence generation plans (which can be included as part of the value proposition) that feed into clinical trial design to ensure the right evidence if collected to support adoption and market penetration.
“Medilink’s support with Arab, Asia and Africa Health along with FIME has been exceptional. The team’s sterling pre-show planning and onsite support has meant that the meetings were stress free, and highly productive. Both Tom and Melissa are a delight to work with and a credit to Medilink. All of the exhibitions delivered a large number of high-quality leads, most of which have been converted into potential distributors, and or customers.”
Dean C Sleigh
“We have been exhibiting at Medica for almost 25 years. It is the best event for us to meet up with our current customers and distributors, as well as secure new contacts and leads. We easily receive in excess of 100 enquiries, mainly from Europe but further afield too; such as the Middle East. We have been extremely pleased with the continual and invaluable support from the Medilink team, the location and the design of the UK pavilion and we rebooked straight away.